MedTrace Logo

The Emergence of RAS Mutations in Metastatic Colorectal Cancer Patients Receiving Cetuximab Treatment

NCT03401957 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2018-01-17

No results posted yet for this study

Summary

To evaluate the emergence of RAS mutation in patients with metastatic colorectal cancer, circulating free DNA will be analyzed using mass spectrometric genotyping in subjects during cetuximab treatment. The hypothesis of this study is that acquired RAS mutation is responsible for the resistance to cetuximab treatment in wild-type colorectal cancer. The usefulness of liquid biopsy to monitor dynamic genetic alterations in colorectal cancer during treatment will also be investigated in this study.

Conditions

Interventions

DRUG

Cetuximab

Cetuximab-based infusional 5-FU regimen as the 1st line treatment.

DIAGNOSTIC_TEST

liquid biopsy

The blood samples taken from subjects will be evaluated for RAS genotype using MassARRAY technique.

Sponsors & Collaborators

  • National Cheng-Kung University Hospital

    collaborator OTHER

  • Kaohsiung Medical University Chung-Ho Memorial Hospital

    collaborator OTHER

  • Taipei Veterans General Hospital, Taiwan

    collaborator OTHER_GOV

  • Cathay General Hospital

    collaborator OTHER

  • National Health Research Institutes, Taiwan

    lead OTHER

Principal Investigators

  • Li-Tzong Chen, M.D. · National Institute of Cancer Research, National Health Research Institutes

Eligibility

Min Age
20 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-31
Primary Completion
2022-01-31
Completion
2022-01-31

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03401957 on ClinicalTrials.gov